Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068248 | 0.85 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8550289 | 0.83 | RAB9A (0.47) | SMN1; SMN2CYP3A4TDP1TSHRALDH1A1 | |
| SCHEMBL16599987 | 0.79 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30513253 | 0.79 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28152848 | 0.73 | TSHR (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4470759 | 0.70 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26493679 | 0.70 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL570471 | 0.70 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4159419 | 0.69 | TSHR (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31409354 | 0.69 | TSHR (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
| EP-0714393-B1 | THIAZOLES AS ANTIVIRAL | PFIZER (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5789408-A | Antiviral thiazoles | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0714393-A1 | THIAZOLES AS ANTIVIRAL | PFIZER INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005378-A1 | ANTIVIRAL THIAZOLES | PFIZER INC. (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | CA12 2698/4885CA1 1962/4885CA2 4123/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | CA12 2698/4885CA1 1962/4885CA2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.